Medical/Pharmaceuticals
Kazia Therapeutics Reports Complete Ex Vivo Disruption of Large Circulating Tumor Cell Clusters in Stage IV HER2-Positive Breast Cancer with Paxalisib Monotherapy
SYDNEY, Sept. 11, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced new findings from a collaborative research program led by ProfessorSudha Rao at QIMR Berghofer. In this ex vivo study, blood samples from Stage IV HER2-...
2025-09-11 20:00
2960
Lundbeck showcases new clinical migraine data, including long-term preventive effectiveness of Vyepti® (eptinezumab) in patients severely impacted by migraine
* Lundbeck demonstrates leadership and unwavering commitment to advancing migraine management and supporting patient outcomes with six presentations at the 2025 International Headache Congress (IHC), including three oral presentations on eptinezumab (Vypeti®) and Lu AG09222 (anti-PACAP mAb) *...
2025-09-11 14:56
1379
HaemaLogiX wins "Most Promising CAR-T Pipeline in APAC" at the Asia Pacific CGT¹ Excellence Awards 2025
SYDNEY, Sept. 11, 2025 /PRNewswire/ -- HaemaLogiX Ltd, a clinical stage Australian biotech, developing novel immunotherapies for patients with blood cancers and B-cell diseases, was honoured to be awarded the"Most Promising CAR-T Pipeline in APAC" at the Asia Pacific CGT Excellence Awards 2025, h...
2025-09-11 11:52
1757
Amaran Biotech Wins Asia-Pacific Biologics CDMO Excellence Award for "Best Fill-Finish"
50-Person Team Demonstrates Taiwan's Biotech Strength HSINCHU, Sept. 11, 2025 /PRNewswire/ -- Amaran Biotech, a next-generation Contract Development and Manufacturing Organization (CDMO), was awarded the "Best Fill-Finish" at the 2025 Asia-Pacific Biologics CDMO Excellence Awards held inSingapore...
2025-09-11 10:00
2078
Fosun International Recognized among Fortune's 2025 "Most Admired Chinese Companies" List
HONG KONG, Sept. 11, 2025 /PRNewswire/ -- On 9 September, Fortune China magazine released its 2025 list of "Most Admired Chinese Companies", in which Fosun International Limited ("Fosun International" or the "Company") (HKEX stock code: 00656) was included in the Industry Star List. This highligh...
2025-09-11 09:00
2856
XingImaging in partnership with SynuSight was awarded a grant from The Michael J. Fox Foundation to support development of the α-synuclein PET tracer 18F-FD4 for Parkinson's disease
NEW HAVEN, Conn., Sept. 11, 2025 /PRNewswire/ -- XingImaging in partnership with SynuSight Biotech has received funding of$3.84M from The Michael J. Fox Foundation to conduct studies on18F-FD4, a specific α-synuclein (α-syn)-targeted PET tracer. Based on prior investigator-initiated trials, the ...
2025-09-11 05:06
998
TVM Capital Healthcare Announces First Closing of its USD 150 Million Southeast Asia Fund
SINGAPORE, Sept. 11, 2025 /PRNewswire/ -- TVM Capital Healthcare, a global private equity investor and operator specialized in healthcare growth capital across emerging markets, today announced the first closing of itsUSD 150 million TVM Healthcare Southeast Asia Fund ("SEA Fund"). The SEA Fund ...
2025-09-11 02:39
2203
Shineco Achieves Mass Production of High-Purity Physical Phospholipids, Breaking Foreign Monopoly and Unlocking Innovation Across Industries
BEIJING, Sept. 10, 2025 /PRNewswire/ -- Shineco Inc. (NASDAQ: SISI) ("Shineco" or the "Company"), a leading developer of induced pluripotent stem cell (iPSC) technology platforms, today announced that its subsidiary, Fuzhou Meidashan Biotechnology Co., Ltd., has successfully achieved large-scale ...
2025-09-10 21:30
1159
C-Ray Therapeutics Supports Mednovo's Phase III Clinical Trial with First Patient Dosed for Lutetium [177Lu] Oxodotreotide Injection
CHENGDU, China, Sept. 10, 2025 /PRNewswire/ -- August 22, 2025, Mednovo Group Co., Ltd. ("Mednovo") announced that the first patient has been successfully dosed in its Phase III clinical trial of Lutetium [177Lu] Oxodotreotide Injection, a Class 3 targeted radiotherapeutic drug. As the exclusive...
2025-09-10 21:30
1092
Imaging Endpoints Announces Patent Application for AI Review Charter System
SCOTTSDALE, Ariz., Sept. 10, 2025 /PRNewswire/ -- Imaging Endpoints (IE), the global leader in Imaging CRO technologies and services for oncology trials, announced the filing of a provisional patent application for its revolutionary AI enhanced Imaging Review Charter (IRC) system. This innovative...
2025-09-10 21:00
1018
LakeShore Biopharma Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee
BEIJING, Sept. 10, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB, "LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious ...
2025-09-10 20:10
1208
Optain Health Closes $26 Million Series A to Bring Oculomics to Primary Care and Beyond
Insight Partners leads; seven major U.S. health systems join. Funding accelerates the global rollout of Optain's advanced robotic retinal imaging, AI, and teleophthalmology platform. NEW YORK, Sept. 10, 2025 /PRNewswire/ -- Optain Health, a healthcare technology company applying artificial intel...
2025-09-10 20:00
1887
New Public Perception Survey Highlights Fragmented Cancer Care Pathway in the Philippines; Optimism About Digital Innovations
* YouGov survey finds strong belief in value of early detection (76%) but low screening uptake (13%) * Confidence in coordinated care (34%) and in 'one-stop' care (36%) among the lowest inSoutheast Asia * Strongest regional demand for advanced technology in follow-up care and recurrence det...
2025-09-10 14:00
1338
New Public Perception Survey Highlights Fragmented Cancer Care Pathway in Thailand; Optimism About Digital Innovations
* YouGov survey finds strong belief in value of early detection (88%) but under half screened (40%) * 84% of respondents aware post-treatment care exists, 55% lack understanding of what it involves * Findings show confidence in "one-stop" cancer services and cautious optimism for digital in...
2025-09-10 11:39
1987
New Public Perception Survey Highlights Fragmented Cancer Care Pathway in Indonesia; Optimism About Digital Innovations
* YouGov survey finds belief in value of early detection (65%) but very low screening uptake (8%) * 76% of respondents aware post-treatment care exists, 58% lack understanding of what it involves * Confidence in coordinated care (39%) and in 'one-stop' care (31%) among lowest inSoutheast As...
2025-09-10 11:24
2081
ImmVira Announces First-in-Human Data of Engineered Exosome MVR-EX105 for Fat Reduction and Muscle Preservation by Topical Application at 2025 Annual Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders
SUZHOU, China, Sept. 9, 2025 /PRNewswire/ -- ImmVira Group ("ImmVira" or the "Company") recently announced that its lead engineered exosome candidate, MVR-EX105 ("EX105") is featured in a poster presentation at the 2025 Annual Congress of the International Federation for the Surgery of Obesity an...
2025-09-10 10:49
1127
Cadonilimab(PD-1/CTLA-4) plus Pulocimab (VEGFR-2) Combination Therapy Shows Promising Results in IO-Resistant Non-Small Cell Lung Cancer in Oral Presentation at the 2025 WCLC
HONG KONG, Sept. 9, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) announced that data from a Phase Ib/II clinical study evaluating the combination of cadonilimab and pulocimab (an anti-VEGFR-2 antibody) in patients with immunotherapy (IO)-resistant NSCLC were presented in a Mini Oral session at the ...
2025-09-10 10:40
1202
Telix Doses First Patient in Phase 3 BiPASS Trial: PSMA-PET Imaging for Prostate Cancer Diagnosis
MELBOURNE, Australia and INDIANAPOLIS, Sept. 10, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces it has dosed the first patient in a Phase 3 clinical trial aimed at expanding the indications for Illuccix® and Gozellix® (kits for the preparation ...
2025-09-10 07:01
1414
iRegene Therapeutics Secures Series B+ Financing Following FDA Fast Track Designation for its Flagship Product NouvNeu001
CHENGDU, China, Sept. 9, 2025 /PRNewswire/ -- iRegene Therapeutics (Chengdu) Co., Ltd. ("iRegene" or the "Company"), a biotechnology company pioneering chemically induced allogeneic cell therapy, announced on September 4th the successful completion of its Series B+ financing round, co-led by Nort...
2025-09-09 21:00
1237
Metabolon Partners with China Kadoorie Biobank to Advance Precision Health
The landmark multiomics study will examine how lifestyle, environmental,
socioeconomic, and genetic factors play a significant role in shaping common
diseases
MORRISVILLE, N.C., Sept. 9, 2025 /PRNewswire/ -- Metabolon
2025-09-09 21:00
1364
Week's Top Stories
Most Reposted
One Universal Production Group (OUP) Officially Opens, Reinforcing Its Position as Asia's Leading IP Ecosystem and Tourism Company
[Picked up by 314 media titles]
2025-12-20 09:36
Singapore Airshow 2026 Marks 10th Edition with New Frontiers in Aviation and Space
[Picked up by 309 media titles]
2025-12-18 19:41
Nine Years of Impact: JULO Disburses USD 1.7 Billion in Digital Financing Across Indonesia
[Picked up by 297 media titles]
2025-12-23 14:23
foodpanda Strengthens Merchant Care with Record Onboarding Milestone in Asia
[Picked up by 292 media titles]
2025-12-18 17:15Rosewood Hotel Group Accelerates Global Expansion with On-Track 2025 Openings; Entering New Sector with Its First-Ever Ski Resort
[Picked up by 289 media titles]
2025-12-19 14:40
Most Read
Cognizant and Microsoft Expand Partnership to Advance AI Transformation and Frontier Firm Experiences
2025-12-18 22:00
6775
Tokyo Lifestyle Co., Ltd. Reports First Six Months of Fiscal Year 2026 Financial Results
2025-12-20 05:05
6073